Veozah: Starting Treatment and Follow-Up

The prescriber needs your medical history and full medication list. Veozah is contraindicated with known cirrhosis, severe kidney impairment or end-stage kidney disease, and CYP1A2 inhibitors. These include medicines that can slow fezolinetant breakdown and raise its concentration.

Baseline liver tests include ALT, AST, alkaline phosphatase, and total and direct bilirubin. The clinician uses the laboratory results to assess whether treatment can begin. The label prohibits starting if ALT or AST is at least twice the upper limit of normal or total bilirubin is at least twice that limit.

Ask about medication and laboratory costs separately. An insurer may cover one part of care differently from another. Confirm the actual prescription coverage and the arrangements for required tests before paying for a treatment plan.

Abnormal results can require more frequent testing or discontinuation. Feeling well is not enough to judge liver safety, because enzyme elevations can occur without symptoms. If a test is delayed, contact the prescribing team for instructions about treatment.

FDA strengthened the warning after liver injury was reported following market approval. The testing schedule remains necessary even when hot flashes have improved.

The US dose is one 45 mg tablet once daily, at about the same time each day, with or without food. Swallow it whole with liquid. The label directs against cutting, crushing, or chewing the tablet.

If a dose is missed, the label allows taking it when remembered unless the next scheduled dose is less than twelve hours away. In that case, skip the missed dose and return to the regular schedule. Do not add another tablet to compensate.

Keep medicines in their original labeled container. Tell the pharmacist before adding a new prescription, over-the-counter medicine, or supplement so interactions can be checked throughout treatment.

Stop Veozah immediately and seek medical attention for symptoms suggesting liver injury: new unusual fatigue, reduced appetite, nausea, vomiting, itching, yellow eyes or skin, pale stools, dark urine, or abdominal pain. The clinical team should assess these symptoms and arrange liver tests.

Abdominal pain, diarrhea, insomnia, and back pain are among effects reported in the label's safety trial. Describe when they started and how severe they are. Digestive symptoms can overlap with liver-warning symptoms, so do not assume a new problem is an ordinary effect that can be ignored.

Keep the prescription name available when seeking care. A clinician seeing you outside the prescribing service needs to know that the active ingredient is fezolinetant.

• Record daily hot-flash frequency and how disruptive episodes are.
• Note nights interrupted by sweating and any change after treatment starts.
• Include adverse effects, missed doses, and new medicines.
• Agree when to review symptom benefit and what alternatives are appropriate if treatment is unsuitable.

Veozah treats vasomotor symptoms. Vaginal dryness, persistent insomnia from another cause, mood symptoms, or bone-health concerns may need additional assessment and treatment. Improvement in hot flashes does not establish that every other symptom has the same cause.